诺思格收盘下跌1.70%，滚动市盈率30.48倍，总市值43.65亿元

Core Viewpoint - The company Norse Group's stock closed at 45.2 yuan, down 1.70%, with a rolling PE ratio of 30.48 times and a total market value of 4.365 billion yuan [1] Company Summary - Norse Group (Beijing) Pharmaceutical Technology Co., Ltd. provides integrated drug clinical research and development services for global pharmaceutical companies and research institutions [1] - The main products include clinical trial operation services, clinical trial site management services, data management and statistical analysis services, biological sample testing services, clinical trial consulting services, and clinical pharmacology services [1] - For Q1 2025, the company reported revenue of 173 million yuan, a year-on-year decrease of 2.53%, and a net profit of 26.0737 million yuan, a year-on-year increase of 13.12%, with a gross profit margin of 36.53% [1] Industry Summary - The average PE ratio for the medical services industry is 39.58 times, with a median of 40.60 times, placing Norse Group at the 23rd position within the industry [1] - The industry average market value is 15.597 billion yuan, while the median market value is 5.652 billion yuan [2] - Other companies in the industry have varying PE ratios, with WuXi AppTec at 16.87 times and Kanglong Chemical at 22.16 times, indicating a competitive landscape [2]